In addition, MET (c-MET) gene amplification is another important mechanism and is detectable in approximately 5–22% of NSCLC patients with acquired resistance to first-generation EGFR-TKIs [2–4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.